Biogen is currently facing allegations of engaging in anticompetitive behavior that has purportedly impacted the U.S. market for multiple sclerosis drugs. According to three complaints, Biogen’s actions, along with the involvement of Pharmacy Benefit Managers (PBMs), have reportedly delayed and significantly reduced the availability of generic versions of Tecfidera. These actions allegedly allowed the company to maintain sales of Tecfidera and Vumerity at inflated units and prices, potentially violating antitrust laws.
For a more comprehensive understanding of the legal actions and allegations, this issue has been extensively covered here.